Acute Heart Failure Clinical Trial
— DYVICOfficial title:
Dynamic Variation of Impedance Cardiography (ICG) a Diagnostic Tool of Acute Heart Failure (AHF) in Emergency Department (ED) Patients Admitted for Acute Dyspnea
NCT number | NCT03241069 |
Other study ID # | DYVIC |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | December 2016 |
Verified date | October 2020 |
Source | University of Monastir |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Dynamic variations of bio-impedance measured cardiac output using non pharmacologic intervention (sitting position, passive leg rising and valsalva maneuver) could be used to detect acute heart failure in patients admitted to the ED for dyspnea.
Status | Completed |
Enrollment | 290 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 year old or above - non traumatic acute dyspnea Exclusion Criteria: - age <18 years, - cardio respiratory arrest, - coma, - shock, - need for inotropic or vasoactive drugs, - mechanical ventilation, - severe and sustained rhythm disorders, - severe mitral valve disease, - severe pulmonary arterial hypertension - renal insufficiency with creatinine>150 µmol/l. |
Country | Name | City | State |
---|---|---|---|
Tunisia | Emergency Department | Monastir |
Lead Sponsor | Collaborator |
---|---|
University of Monastir |
Tunisia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiac output rate measured by ICG before and during maneuvers in acute dyspneic patients between the AHF and non AHF groups | The diagnostic performance of each maneuver is evaluated by calculating the CO in ml/min by bio-impedance technique and compare the values between patients with and without AHF and between baseline.
The diagnosis of AHF is based on clinical, biological (BNP levels), radiological (chest X-ray) and cardiac ultrasound data. |
12 hours | |
Secondary | In hospital death | survivor or ,ot | up to 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03720288 -
Acetazolamide in Patients With Acute Heart Failure
|
Phase 3 |